Drugs & Targets C2i Genomics, AstraZeneca to collaborate on MRD test for clinical R&D January 06, 2023Vol.49 No.01
Drugs & Targets Gilead to acquire remaining rights to immunotherapy GS-1811 from Jounce January 06, 2023Vol.49 No.01
Drugs & Targets FDA approves updated drug labeling for Xeloda tablets under Project Renewal December 16, 2022Vol.48 No.45
Drugs & Targets Tecentriq receives FDA approval for alveolar soft part sarcoma December 16, 2022Vol.48 No.45
Drugs & Targets Krazati receives FDA accelerated approval for KRAS G12C-mutated NSCLC December 16, 2022Vol.48 No.45
Drugs & Targets FDA approves Rezlidhia for R/R AML with a susceptible IDH1 mutation December 02, 2022Vol.48 No.43
Drugs & Targets Genentech voluntarily withdraws U.S. indication of Tecentriq for types of bladder cancer December 02, 2022Vol.48 No.43
Drugs & Targets AstraZeneca to acquire Neogene Therapeutics for $320M to develop T cell receptor therapies December 02, 2022Vol.48 No.43
